+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review



Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review



Schizophrenia Bulletin 38(5): 1003-1011



When schizophrenia patients have insufficient response to clozapine, pharmacological augmentation is often applied. This meta-analysis summarizes available evidence on efficacy of pharmacological augmentation of clozapine treatment in schizophrenia spectrum disorder. Only double-blind randomized controlled studies were included. Primary outcome measure was total symptom severity, and secondary outcome measures were subscores for positive and negative symptoms. Effect sizes were calculated from individual studies and combined to standardized mean differences (Hedges's g). Twenty-nine studies reporting on 15 different augmentations were included. Significant better efficacy than placebo on total symptom severity was observed for lamotrigine, citalopram, sulpiride, and CX516 (a glutamatergic agonist). The positive effect of lamotrigine disappeared after outlier removal. The other positive findings were based on single studies. Significantly better efficacy on positive symptom severity was observed for topiramate and sulpiride. The effect of topiramate disappeared after outlier removal. Results for sulpiride were based on a single randomized controlled trial. Citalopram, sulpiride, and CX516 showed better efficacy for negative symptoms than placebo, all based on single studies. Evidence for efficacy of clozapine augmentation is currently scarce. Efficacy of lamotrigine and topiramate were both dependent on single studies with deviating findings. The effect of citalopram, sulpiride, and CX516 were based on single studies. Thus, despite their popularity, pharmacological augmentations of clozapine are not (yet) demonstrated to be superior to placebo.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054960707

Download citation: RISBibTeXText

PMID: 21422107

DOI: 10.1093/schbul/sbr004


Related references

Augmentation strategies in patients with schizophrenia who show partial response to clozapine treatment. Turk Psikiyatri Dergisi 25(3): 201-211, 2014

Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine. Expert Opinion on PharmacoTherapy 15(16): 2329-2345, 2014

Sex hormones and oxytocin augmentation strategies in schizophrenia: A quantitative review. Schizophrenia Research 168(3): 603-613, 2015

Pharmacological strategies for clozapine-induced hypersalivation: treatment with botulinum toxin B in one patient and review of the literature. Der Nervenarzt 76(2): 205-208, 2005

Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophrenia Research 143(1): 207-214, 2013

Augmentation of Clozapine With Paliperidone in Schizophrenia Patients With Partial Response to Treatment: A Case Series. Turk Psikiyatri Dergisi 27(1): 57-62, 2016

Augmentation strategies in clozapine-resistant schizophrenia. Cns Drugs 19(10): 843-872, 2005

Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatrica Scandinavica 110(4): 292-298, 2004

Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia. Clinical Neuropharmacology 29(1): 28-33, 2006

Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the 'real world'. Acta Psychiatrica Scandinavica 126(1): 40-46, 2012

Levothyroxine Augmentation in Clozapine Resistant Schizophrenia: A Case Report and Review. Case Reports in Psychiatry 2015: 678040, 2015

Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis. Pharmacopsychiatry 47(7): 231-238, 2015

Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature. Schizophrenia Research 152(1): 255-260, 2014

Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. American Journal of Psychiatry 153(12): 1625-1627, 1996

Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40(5): 722-747, 1990